Replies to post #32912 on Cel Sci Corporation (CVM)

[boozeman]

He/she seems to bounce back and forth on statements concerning trial validity. Says most likely failure, then goes onto say slight benefit and scooped up by big pharma. Overall bearish sentiment and that’s scary because he/she is obviously an educated individual that practices in the profession of cancer treatment. Come on Geert, shock the world......PLEASE!

[Kpauliukonis]

Your point 5B totally misses the point. The concept here is to treat with mk to enhance the activity of the native immune system, and to do so requires treatment prior to SOC modalities. If that’s your concept, why would you start treating in metastatic and recurrent cases where the native immune system has already been damaged? I don’t get your point.

As far as your prediction of the outcome, meh. We shall see soon enough.

[Indoreservoir]

GD

I'm confused who you are writing your post to - it is not in reply to any post, and it seems addressed to Soxrates. You then suggest that Soxrates has insulted you somehow. What/where????

You say you have no financial stake yet in a post on Saturday, 15 Aug you said you had August calls.

You then suggest an announcement on 18 August with data preparation up to the 17th, and you 'forgot' the stated plan by CVM to notify the FDA before they announce anything. When will they do that? Wee hours of the 18th?

Then you proceed with grammatically-challenged comments about the extent of your and the industry's knowledge, and suggest the trial is likely to fail for some reasons I cannot understand. You completely ignore Phase 2 trial results and intimate the whole thing is based on preclinical work.

Frankly, I think we should not believe much of what you say given these simple inconsistencies and lack of thoroughness. A bit of cherry picking of facts, seems to me. Why, I don't know.

I may be wrong and in any event no offense intended. All IMHO.

GLTAL